AAV-directed muscular dystrophy gene therapy

Bibliography

• Athanasopoulos T, Graham IR, Foster H, Dickson G. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 2004;11(Suppl 1):S109-21
   PubMed Web of Science ®Google Scholar
• Laughlin CA, Tratschin JD, Coon H, Carter BJ. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 1983;23:65-73
   PubMed Web of Science ®Google Scholar
• Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982;79:2077-81
   PubMed Web of Science ®Google Scholar
• Hermonat PL, Labow MA, Wright R, Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol 1984;51:329-39
   PubMedGoogle Scholar
• Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol 1983;45:555-64
   PubMed Web of Science ®Google Scholar
• Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol 1984;51:611-19
   PubMed Web of Science ®Google Scholar
• Xie Q, Bu W, Bhatia S, The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 2002;99:10405-10
   PubMed Web of Science ®Google Scholar
• Song S, Lu Y, Choi YK, DNA-dependent PK inhibits adeno-associated virus DNA integration. Proc Natl Acad Sci USA 2004;101:2112-16
   PubMed Web of Science ®Google Scholar
• Penaud-Budloo M, Le Guiner C, Nowrouzi A, Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol 2008;82:7875-85
   PubMed Web of Science ®Google Scholar
• Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996;70:8098-108
   PubMed Web of Science ®Google Scholar
• Kessler PD, Podsakoff GM, Chen X, Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996;93:14082-7
   PubMed Web of Science ®Google Scholar
• Manno CS, Chew AJ, Hutchison S, AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101:2963-72
   PubMed Web of Science ®Google Scholar
• Jung SC, Han IP, Limaye A, Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 2001;98:2676-81
   PubMed Web of Science ®Google Scholar
• Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008;8:911-22
   PubMed Web of Science ®Google Scholar
• Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000;97:13714-19
   PubMed Web of Science ®Google Scholar
• Gregorevic P, Allen JM, Minami E, rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006;12:787-9
   PubMed Web of Science ®Google Scholar
• Wang B, Li J, Fu FH, Xiao X. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J Orthop Res 2009;27:421-6
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhu T, Qiao C, Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005;23:321-8
   PubMed Web of Science ®Google Scholar
• Inagaki K, Fuess S, Storm TA, Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006;14:45-53
   PubMed Web of Science ®Google Scholar
• Schaffer DV, Maheshri N. Directed evolution of AAV mutants for enhanced gene delivery. Conf Proc IEEE Eng Med Biol Soc 2004;5:3520-3
   PubMedGoogle Scholar
• Yu CY, Yuan Z, Cao Z, A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 2009;16(8):953-62
   PubMed Web of Science ®Google Scholar
• Zhong L, Li B, Mah CS, Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008;105:7827-32
   PubMed Web of Science ®Google Scholar
• Qiao C, Zheng H, Yuan Z, Comparison of transduction efficiency of tryosine-mutant AAV vectors in muscle. Mol Ther 2009;17:S175
   Google Scholar
• Zhang W, Yue Y, Ghosh A, Novel tryosine mutant vectors expand the utilities of AAV-mediated muscle gene therapy. Mol Ther 2009;17:S176
   Google Scholar
• Van Vliet KM, Blouin V, Brument N, The role of the adeno-associated virus capsid in gene transfer. Methods Mol Biol 2008;437:51-91
   PubMedGoogle Scholar
• Rodino-Klapac LR, Chicoine LG, Kaspar BK, Mendell JR. Gene therapy for duchenne muscular dystrophy: expectations and challenges. Arch Neurol 2007;64:1236-41
   PubMed Web of Science ®Google Scholar
• Chirmule N, Xiao W, Truneh A, Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000;74:2420-5
   PubMed Web of Science ®Google Scholar
• Sun JY, Anand-Jawa V, Chatterjee S, Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003;10:964-76
   PubMed Web of Science ®Google Scholar
• Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006;14:316-27
   PubMed Web of Science ®Google Scholar
• Le Bec C, Douar AM. Gene therapy progress and prospects–vectorology: design and production of expression cassettes in AAV vectors. Gene Ther 2006;13:805-13
   PubMed Web of Science ®Google Scholar
• Mccarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001;8:1248-54
   PubMed Web of Science ®Google Scholar
• Wang Z, Ma HI, Li J, Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003;10:2105-11
   PubMed Web of Science ®Google Scholar
• Ghahramani Seno MM, Graham IR, Athanasopoulos T, RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology. Hum Mol Genet 2008;17:2622-32
   PubMed Web of Science ®Google Scholar
• Warrington KH Jr, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006;119:571-603
   PubMed Web of Science ®Google Scholar
• Zhu T, Zhou L, Mori S, Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 2005;112:2650-9
   PubMed Web of Science ®Google Scholar
• Foster K, Foster H, Dickson JG. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 2006;13:1677-85
   PubMed Web of Science ®Google Scholar
• Thirion C, Lochmuller H. Current status of gene therapy for muscle diseases. Drug News Perspect 2007;20:357-63
   PubMed Web of Science ®Google Scholar
• Qiao C, Li J, Jiang J, Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 2008;19:241-54
   PubMed Web of Science ®Google Scholar
• Duan D, Yue Y, Yan Z, Engelhardt JF. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 2000;6:595-8
   PubMed Web of Science ®Google Scholar
• Nakai H, Storm TA, Kay MA. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 2000;18:527-32
   PubMed Web of Science ®Google Scholar
• Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000;6:599-602
   PubMed Web of Science ®Google Scholar
• Li J, Sun W, Wang B, Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum Gene Ther 2008;19:958-64
   PubMed Web of Science ®Google Scholar
• Lai Y, Yue Y, Liu M, Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 2005;23:1435-9
   PubMed Web of Science ®Google Scholar
• Dai J, Rabie AB. The use of recombinant adeno-associated virus for skeletal gene therapy. Orthod Craniofac Res 2007;10:1-14
   PubMed Web of Science ®Google Scholar
• Jazwa A, Jozkowicz A, Dulak J. New vectors and strategies for cardiovascular gene therapy. Curr Gene Ther 2007;7:7-23
   PubMed Web of Science ®Google Scholar
• Judge LM, Chamberlain JS. Gene therapy for Duchenne muscular dystrophy: AAV leads the way. Acta Myol 2005;24:184-93
   PubMedGoogle Scholar
• Watchko J, O'day T, Wang B, Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther 2002;13:1451-60
   PubMed Web of Science ®Google Scholar
• Wang Z, Kuhr CS, Allen JM, Sustained AAV-mediated dystrophin expression in a canine model of duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007;15:1160-6
   PubMed Web of Science ®Google Scholar
• Monahan PE, Samulski RJ, Tazelaar J, Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998;5:40-9
   PubMed Web of Science ®Google Scholar
• Li J, Dressman D, Tsao YP, rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther 1999;6:74-82
   PubMed Web of Science ®Google Scholar
• Xiao X, Li J, Tsao YP, Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000;74:1436-42
   PubMed Web of Science ®Google Scholar
• Melo LG, Agrawal R, Zhang L, Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002;105:602-7
   PubMed Web of Science ®Google Scholar
• Yue Y, Li Z, Harper SQ, Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 2003;108:1626-32
   PubMed Web of Science ®Google Scholar
• Chu D, Thistlethwaite PA, Sullivan CC, Gene delivery to the mammalian heart using AAV vectors. Methods Mol Biol 2004;246:213-24
   PubMedGoogle Scholar
• Kaspar BK, Roth DM, Lai NC, Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus. J Gene Med 2005;7:316-24
   PubMed Web of Science ®Google Scholar
• Greelish JP, Su LT, Lankford EB, Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 1999;5:439-43
   PubMed Web of Science ®Google Scholar
• Gregorevic P, Blankinship MJ, Allen JM, Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004;10:828-34
   PubMed Web of Science ®Google Scholar
• Pacak CA, Mah CS, Thattaliyath BD, Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006;99:e3-9
   PubMed Web of Science ®Google Scholar
• Yue Y, Ghosh A, Long C, A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 2008;16:1944-52
   PubMed Web of Science ®Google Scholar
• Kornegay J, Li J, Bogan J, Widespread muscle expression of an AAV-9 human mini-dystrophin construct after systemic intravenous injection in golden retriever muscular dystrophy (GRMD) neonatal dogs. Mol Ther 2009;17:S152
   Google Scholar
• Li J, Bogan J, Chen C, Hydrodynamic limb vein injection of AAV9 results in regional and systemic long-term expression of minidystrophin in young adult GRMD dogs. Mol Ther 2009;17:S278
   Google Scholar
• Wang B, Li J, Fu FH, Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 2008;15:1489-99
   PubMed Web of Science ®Google Scholar
• Harms JS, Splitter GA. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther 1995;6:1291-7
   PubMed Web of Science ®Google Scholar
• Hartigan-O'connor D, Kirk CJ, Crawford R, Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 2001;4:525-33
   PubMed Web of Science ®Google Scholar
• Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther 2002;9:1576-88
   PubMed Web of Science ®Google Scholar
• Donoviel DB, Shield MA, Buskin JN, Analysis of muscle creatine kinase gene regulatory elements in skeletal and cardiac muscles of transgenic mice. Mol Cell Biol 1996;16:1649-58
   PubMed Web of Science ®Google Scholar
• Larochelle N, Oualikene W, Dunant P, The short MCK1350 promoter/enhancer allows for sufficient dystrophin expression in skeletal muscles of mdx mice. Biochem Biophys Res Commun 2002;292:626-31
   PubMed Web of Science ®Google Scholar
• Shield MA, Haugen HS, Clegg CH, Hauschka SD. E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice. Mol Cell Biol 1996;16:5058-68
   PubMed Web of Science ®Google Scholar
• Weeratna RD, Wu T, Efler SM, Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther 2001;8:1872-8
   PubMed Web of Science ®Google Scholar
• Cordier L, Gao GP, Hack AA, Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001;12:205-15
   PubMed Web of Science ®Google Scholar
• Harper SQ, Hauser MA, Dellorusso C, Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002;8:253-61
   PubMed Web of Science ®Google Scholar
• Cordier L, Hack AA, Scott MO, Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol Ther 2000;1:119-29
   PubMed Web of Science ®Google Scholar
• Hauser MA, Robinson A, Hartigan-O'connor D, Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther 2000;2:16-25
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Yuasa K, Yoshimura M, Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002;293:1265-72
   PubMed Web of Science ®Google Scholar
• Draghia-Akli R, Fiorotto ML, Hill LA, Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat Biotechnol 1999;17:1179-83
   PubMed Web of Science ®Google Scholar
• Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol 1999;17:241-5
   PubMed Web of Science ®Google Scholar
• Salva MZ, Himeda CL, Tai PW, Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 2007;15:320-9
   PubMed Web of Science ®Google Scholar
• Allamand V, Campbell KP. Animal models for muscular dystrophy: valuable tools for the development of therapies. Hum Mol Genet 2000;9:2459-67
   PubMed Web of Science ®Google Scholar
• Watchko JF, O'day TL, Hoffman EP. Functional characteristics of dystrophic skeletal muscle: insights from animal models. J Appl Physiol 2002;93:407-17
   PubMed Web of Science ®Google Scholar
• Guo C, Willem M, Werner A, Absence of alpha7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet 2006;15:989-98
   PubMed Web of Science ®Google Scholar
• Li D, Long C, Yue Y, Duan D. Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice. Hum Mol Genet 2009;18:1209-20
   PubMed Web of Science ®Google Scholar
• Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-28
   PubMed Web of Science ®Google Scholar
• Koenig M, Hoffman EP, Bertelson CJ, Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-17
   PubMed Web of Science ®Google Scholar
• Kunkel LM. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 1986;322:73-7
   PubMed Web of Science ®Google Scholar
• Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends Mol Med 2007;13:520-6
   PubMed Web of Science ®Google Scholar
• Koenig M, Kunkel LM. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J Biol Chem 1990;265:4560-6
   PubMed Web of Science ®Google Scholar
• Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988;53:219-28
   PubMed Web of Science ®Google Scholar
• Bonilla E, Samitt CE, Miranda, Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 1988;54:447-52
   PubMed Web of Science ®Google Scholar
• Miranda AF, Francke U, Bonilla E, Dystrophin immunocytochemistry in muscle culture: detection of a carrier of Duchenne muscular dystrophy. Am J Med Genet 1989;32:268-73
   PubMed Web of Science ®Google Scholar
• Senter L, Luise M, Presotto C, Interaction of dystrophin with cytoskeletal proteins: binding to talin and actin. Biochem Biophys Res Commun 1993;192:899-904
   PubMed Web of Science ®Google Scholar
• Hemmings L, Kuhlman PA, Critchley DR. Analysis of the actin-binding domain of alpha-actinin by mutagenesis and demonstration that dystrophin contains a functionally homologous domain. J Cell Biol 1992;116:1369-80
   PubMed Web of Science ®Google Scholar
• Amann KJ, Renley BA, Ervasti JM. A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J Biol Chem 1998;273:28419-23
   PubMed Web of Science ®Google Scholar
• Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991;66:1121-31
   PubMed Web of Science ®Google Scholar
• Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle cells. J Cell Biol 1995;128:355-61
   PubMed Web of Science ®Google Scholar
• Chan YM, Bonnemann CG, Lidov HG, Kunkel LM. Molecular organization of sarcoglycan complex in mouse myotubes in culture. J Cell Biol 1998;143:2033-44
   PubMed Web of Science ®Google Scholar
• Henry MD, Campbell KP. Dystroglycan: an extracellular matrix receptor linked to the cytoskeleton. Curr Opin Cell Biol 1996;8:625-31
   PubMed Web of Science ®Google Scholar
• Hoffman EP, Knudson CM, Campbell KP, Kunkel LM. Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 1987;330:754-8
   PubMed Web of Science ®Google Scholar
• Lapidos KA, Kakkar R, Mcnally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004;94:1023-31
   PubMed Web of Science ®Google Scholar
• Williams IA, Allen DG. Intracellular calcium handling in ventricular myocytes from mdx mice. Am J Physiol Heart Circ Physiol 2007;292:H846-55
   Google Scholar
• Sicinski P, Geng Y, Ryder-Cook AS, The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989;244:1578-80
   PubMed Web of Science ®Google Scholar
• Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984;81:1189-92
   PubMed Web of Science ®Google Scholar
• Heslop L, Morgan JE, Partridge TA. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. J Cell Sci 2000;113(Pt 12):2299-308
   PubMed Web of Science ®Google Scholar
• England SB, Nicholson LV, Johnson MA, Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990;343:180-2
   PubMed Web of Science ®Google Scholar
• Crawford GE, Faulkner JA, Crosbie RH, Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol 2000;150:1399-410
   PubMed Web of Science ®Google Scholar
• Rafael JA, Cox GA, Corrado K, Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 1996;134:93-102
   PubMed Web of Science ®Google Scholar
• Wang B, Li J, Qiao C, A canine minidystrophin is functional and therapeutic in mdx mice. Gene Ther 2008;15:1099-106
   PubMed Web of Science ®Google Scholar
• Grady RM, Teng H, Nichol MC, Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997;90:729-38
   PubMed Web of Science ®Google Scholar
• Deconinck AE, Rafael JA, Skinner JA, Utrophin–dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997;90:717-27
   PubMed Web of Science ®Google Scholar
• Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005;20(3):CD003178. Published online: 20 July 2005, doi: 10.1002/14651858.CD003178.pub3
   Google Scholar
• Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990;26:271-7
   PubMed Web of Science ®Google Scholar
• Sanyal SK, Johnson WW, Thapar MK, Pitner SE. An ultrastructural basis for electrocardiographic alterations associated with Duchenne's progressive muscular dystrophy. Circulation 1978;57:1122-9
   PubMed Web of Science ®Google Scholar
• Townsend D, Blankinship MJ, Allen JM, Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 2007;15:1086-92
   PubMed Web of Science ®Google Scholar
• Wang Z, Allen JM, Riddell SR, Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007;18:18-26
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, Fokkema I, Verschuuren J, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009;30:293-9
   PubMed Web of Science ®Google Scholar
• Arnett AL, Chamberlain JR, Chamberlain JS. Therapy for neuromuscular disorders. Curr Opin Genet Dev 2009;19:290-7
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Vulin A, Fougerousse F, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004;306:1796-9
   PubMed Web of Science ®Google Scholar
• Lu QL, Rabinowitz A, Chen YC, Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005;102:198-203
   PubMed Web of Science ®Google Scholar
• Nakamura A, Takeda S. Exon-skipping therapy for Duchenne muscular dystrophy. Neuropathology 2009;29:494-501
   PubMed Web of Science ®Google Scholar
• Ruszczak C, Mirza A, Menhart N. Differential stabilities of alternative exon-skipped rod motifs of dystrophin. Biochim Biophys Acta 2009;1794:921-8
   PubMed Web of Science ®Google Scholar
• Trollet C, Athanasopoulos T, Popplewell L, Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol Ther 2009;9:849-66
   PubMed Web of Science ®Google Scholar
• Van Ommen GJ, Van Deutekom J, Aartsma-Rus A. The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 2008;10:140-9
   PubMed Web of Science ®Google Scholar
• Wu B, Moulton HM, Iversen PL, Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008;105:14814-19
   PubMed Web of Science ®Google Scholar
• Denti MA, Rosa A, D'antona G, Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA 2006;103:3758-63
   PubMed Web of Science ®Google Scholar
• Crosbie RH, Straub V, Yun HY, mdx muscle pathology is independent of nNOS perturbation. Hum Mol Genet 1998;7:823-9
   PubMed Web of Science ®Google Scholar
• Zhuang W, Eby JC, Cheong M, The susceptibility of muscle cells to oxidative stress is independent of nitric oxide synthase expression. Muscle Nerve 2001;24:502-11
   PubMed Web of Science ®Google Scholar
• Thomas GD, Sander M, Lau KS, Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci USA 1998;95:15090-5
   PubMed Web of Science ®Google Scholar
• Lai Y, Thomas GD, Yue Y, Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009;119:624-35
   PubMed Web of Science ®Google Scholar
• Imamura M, Ozawa E. Differential expression of dystrophin isoforms and utrophin during dibutyryl-cAMP-induced morphological differentiation of rat brain astrocytes. Proc Natl Acad Sci USA 1998;95:6139-44
   PubMed Web of Science ®Google Scholar
• Tinsley JM, Potter AC, Phelps SR, Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 1996;384:349-53
   PubMed Web of Science ®Google Scholar
• Wakefield PM, Tinsley JM, Wood MJ, Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther 2000;7:201-4
   PubMed Web of Science ®Google Scholar
• Cerletti M, Negri T, Cozzi F, Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther 2003;10:750-7
   PubMed Web of Science ®Google Scholar
• Odom GL, Gregorevic P, Allen JM, Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 2008;16:1539-45
   PubMed Web of Science ®Google Scholar
• Perkins KJ, Davies KE. The role of utrophin in the potential therapy of Duchenne muscular dystrophy. Neuromuscul Disord 2002;12(Suppl 1):S78-89
   Google Scholar
• Gillis JM (2004). Utrophin, a way to cure Duchenne muscle dystrophy. Med Sci (Paris) 2002;20:442-7
   Web of Science ®Google Scholar
• Mcpherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90
   PubMed Web of Science ®Google Scholar
• Tsuchida K. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myol 2008;27:14-8
   PubMedGoogle Scholar
• Bogdanovich S, Perkins KJ, Krag TO, Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 2005;19:543-9
   PubMed Web of Science ®Google Scholar
• Qiao C, Li J, Zheng H, Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther 2009;20(1):1-10
   PubMed Web of Science ®Google Scholar
• Bartoli M, Poupiot J, Vulin A, AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 2007;14:733-40
   PubMed Web of Science ®Google Scholar
• Messina S, Mazzeo A, Bitto A, VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J 2007;21:3737-46
   PubMed Web of Science ®Google Scholar
• Acharyya S, Villalta SA, Bakkar N, Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007;117:889-901
   PubMed Web of Science ®Google Scholar
• Bogdanovich S, Perkins KJ, Krag TO, Khurana TS. Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. J Mol Med 2004;82:102-15
   PubMed Web of Science ®Google Scholar
• Fougerousse F, Bartoli M, Poupiot J, Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector. Mol Ther 2007;15:53-61
   PubMed Web of Science ®Google Scholar
• Pacak, CA, Walter GA, Gaidosh G, Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther 2007;15:1775-81
   PubMed Web of Science ®Google Scholar
• Daniele N, Richard I, Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies. Int J Biochem Cell Biol 2007;39:1608-24
   PubMed Web of Science ®Google Scholar
• Dressman D, Araishi K, Imamura M, Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity. Hum Gene Ther 2002;13:1631-46
   PubMed Web of Science ®Google Scholar
• Kawada T, Masui F, Kumagai H, A novel paradigm for therapeutic basis of advanced heart failure–assessment by gene therapy. Pharmacol Ther 2005:107:31-43
   PubMed Web of Science ®Google Scholar
• Rodino-Klapac LR, Lee JS, Mulligan RC, Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology 2008;71:240-7
   PubMed Web of Science ®Google Scholar
• Melacini P, Fanin M, Duggan DJ, Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 1999;22:473-9
   PubMed Web of Science ®Google Scholar
• Nigro V, Okazaki Y, Belsito A, Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997;6:601-7
   PubMed Web of Science ®Google Scholar
• Straub V, Duclos F, Venzke DP, Molecular pathogenesis of muscle degeneration in the δ-sarcoglycan-deficient hamster. Am J Pathol 1998;153:1623-30
   PubMed Web of Science ®Google Scholar
• Stedman H, Wilson JM, Finke R, Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or Δ-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther 2000;11:777-90
   PubMedGoogle Scholar
• Muntoni F, Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 2007;20:590-4
   PubMed Web of Science ®Google Scholar
• Frank KM, Hogarth DK, Miller JL, Investigation of the cause of death in a gene-therapy trial. N Engl J Med 2009;361:161-9
   PubMed Web of Science ®Google Scholar
• Cooper BJ, Winand NJ, Stedman H, The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 1988;334:154-6
   PubMed Web of Science ®Google Scholar
• Kornegay JN, Sharp NJ, Schueler RO, Betts CW. Tarsal joint contracture in dogs with golden retriever muscular dystrophy. Lab Anim Sci 1994;44:331-3
   PubMedGoogle Scholar
• Fougerousse F, Gonin P, Durand M, Force impairment in calpain 3-deficient mice is not correlated with mechanical disruption. Muscle Nerve 2003;27:616-23
   PubMed Web of Science ®Google Scholar
• Bartoli M, Roudaut C, Martin S, Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther 2006;13:250-9
   PubMed Web of Science ®Google Scholar
• Duclos F, Straub V, Moore SA, Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol 1998;142:1461-71
   PubMed Web of Science ®Google Scholar
• Araishi K, Sasaoka T, Imamura M, Loss of the sarcoglycan complex and sarcospan leads to muscular dystrophy in beta-sarcoglycan-deficient mice. Hum Mol Genet 1999;8:1589-98
   PubMed Web of Science ®Google Scholar
• Guo LT, Zhang XU, Kuang W, Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul Disord 2003;13:207-15
   Google Scholar
• Qiao C, Li J, Zhu T, Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci USA 2005;102:11999-2004
   PubMed Web of Science ®Google Scholar
• Liu M, Yue Y, Harper SQ, Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 2005;11:245-56
   PubMed Web of Science ®Google Scholar
• Fabb SA, Wells DJ, Serpente P, Dickson G. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet 2002;11:733-41
   PubMed Web of Science ®Google Scholar